Presbia appointed Dr Gerd Auffarth to the Board of Directors

– IRELAND, Dublin – Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near vision restoration, announced today that it has appointed Dr. Gerd Auffarth, M.D., Ph.D. to the board. The board also announced the appointment of Dr. Mark Blumenkranz to the Presbia Medical Advisory Board.

Dr. Auffarth is Director of the International Vision Correction Research Centre (IVCRC) and The David J. Apple International Laboratory for Ophthalmic Pathology. Dr. Auffarth has his M.D. degree from RWTH Aachen Medical School, Aachen University of Technology in Germany. Dr. Auffarth’s core research is in cornea, corneal surgery, presbyopia, cataracts and intraocular lens implants. His expertise is in IOL’s, multi-focal IOL’s, refractive laser technologies and presbyopia surgery. Dr. Auffarth is considered a pioneer in Femtosecond laser surgery. In an article published by The Ophthalmologist Dr. Auffarth was ranked among the top 20 ophthalmologists in the world.

Dr. Auffarth was quoted as follows: “In my opinion, Presbia is the leading solution for the world’s population effected by presbyopia. I am very impressed with the Presbia Microlens implants and have found patient outcomes, adaptation and lack of adverse events to be superior. I’m very proud to be joining the Presbia Board of Directors and in devoting myself to Presbia’s overall strategy, the successful launch outside the U.S. and in supporting the current U.S. clinical trials.”

Mark S. Blumenkranz, M.D., is the H.J. Smead Professor in the Department of Ophthalmology at Stanford University. He received his undergraduate and medical education at Brown University, and completed a residency in Ophthalmology at Stanford University and a fellowship in vitreoretinal diseases at the Bascom Palmer Eye Institute. Dr. Blumenkranz transitions from the Presbia Board of Directors to join the Presbia Medical Advisory Board. Dr. Blumenkranz was quoted as follows: “I’ve enjoyed my association with Presbia as a Director for the past several years and look forward to my continued involvement through the Medical Advisory Board.”

Randy Thurman, Chairman of the Board, Presbia PLC said: “We thank Dr. Blumenkranz for his prior service and continuing involvement through the Presbia Medical Advisory Board. It is an honor to have Dr. Auffarth on our Board of Directors. His decision to join underscores our goal of Presbia’s Microlens to meet the needs of millions of presbyopic patients worldwide. His reputation is not only well established throughout Europe but his leadership in South Korea and other Asian countries, aligns perfectly with our commercialization strategy.”

About Presbia

Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has developed and is currently marketing the presbyopia-correcting Presbia Flexivue Microlens™, a miniature lens that is implanted in a corneal pocket created by a femtosecond laser. The Presbia Flexivue Microlens™ has received a CE mark for the European Economic Area, allowing the lens to be marketed in over 30 countries across Europe. A staged pivotal U.S. clinical trial for the Presbia Flexivue Microlens™ commenced in 2014.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

here the original post =>